12. Reportable Segment Information

The accounting standards for reporting information about operating segments define operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. For financial accounting and reporting purposes, the Company reports its results for the two reportable segments as follows: (1) the Medical Device unit, which is comprised of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing; as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, neuro-vascular and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings. During fiscal 2016, the Company acquired Creagh Medical and NorMedix, which are included in the Medical Device segment.

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2017			2016			2015
Revenue:
Medical Device	$	53,983		$	53,202		$	45,944
In Vitro Diagnostics		19,129			18,164			15,954
Total revenue	$	73,112		$	71,366		$	61,898

Operating income (loss):
Medical Device	$	6,902		$	16,975		$	21,192
In Vitro Diagnostics		8,293			7,115			4,484
Total segment operating income		15,195			24,090			25,676
Corporate		(8,092	)		(7,231	)		(6,587	)
Total operating income	$	7,103		$	16,859		$	19,089

Depreciation and amortization:
Medical Device	$	4,453		$	3,261		$	1,138
In Vitro Diagnostics		412			789			873
Corporate		690			823			794
Total depreciation and amortization	$	5,555		$	4,873		$	2,805

The Corporate category includes expenses that are not fully allocated to Medical Device and In Vitro Diagnostics segments. These Corporate costs are related to functions, such as executive management, corporate accounting, legal, human resources and Board of Directors. Corporate may also include expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

		2017				2016				2015
Medtronic			18	%			25	%			26	%

The revenue from the customer listed is derived from two primary sources: licensing and product sales (primarily in the Medical Device segment).

Geographic Revenue and Long-lived Assets

Geographic revenue was as follows for the years ended September 30:

	2017			2016			2015
Domestic		77	%		79	%		77	%
Foreign		23	%		21	%		23	%

Long-lived assets, including property and equipment and intangible assets net of accumulated depreciation and amortization, respectively, by country were as follows as of September 30:

	2017		2016
U.S.	$	20,949	$	21,543
Ireland		22,555		20,583